Diamyd Medical 将来の成長

Future 基準チェック /26

Diamyd Medicalの収益は年間10.3%で減少すると予測されていますが、年間収益は年間103%で増加すると予想されています。EPS は年間5.7%で減少すると予想されています。

主要情報

-10.3%

収益成長率

-5.7%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	103.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	22 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:DMN - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
8/31/2027	38	N/A	N/A	N/A	1
8/31/2026	3	-186	-181	-181	1
8/31/2025	3	-159	-139	-155	1
8/31/2024	0	-152	-137	-129	N/A
5/31/2024	0	-140	-144	-135	N/A
2/29/2024	0	-120	-134	-122	N/A
11/30/2023	0	-116	-124	-112	N/A
8/31/2023	1	-116	-122	-111	N/A
5/31/2023	1	-119	-116	-119	N/A
2/28/2023	0	-115	-122	-127	N/A
11/30/2022	1	-99	-114	-120	N/A
8/31/2022	0	-104	-128	-93	N/A
5/31/2022	0	-91	-153	-110	N/A
2/28/2022	1	-106	-147	-99	N/A
11/30/2021	0	-83	-140	-95	N/A
8/31/2021	0	60	-114	-109	N/A
5/31/2021	0	74	-67	-58	N/A
2/28/2021	0	99	-47	-43	N/A
11/30/2020	0	121	5	9	N/A
8/31/2020	0	10	15	17	N/A
5/31/2020	1	13	13	13	N/A
2/29/2020	1	13	11	11	N/A
11/30/2019	1	-35	-35	-35	N/A
8/31/2019	2	-37	-39	-39	N/A
5/31/2019	1	-38	-38	-38	N/A
2/28/2019	0	-43	-38	-38	N/A
11/30/2018	0	-42	-41	-40	N/A
8/31/2018	1	-44	-42	-42	N/A
5/31/2018	1	-39	N/A	-42	N/A
2/28/2018	1	-35	N/A	-38	N/A
11/30/2017	1	-32	N/A	-33	N/A
8/31/2017	1	-26	N/A	-26	N/A
5/31/2017	1	-24	N/A	-20	N/A
2/28/2017	1	-34	N/A	-19	N/A
11/30/2016	1	-32	N/A	-18	N/A
8/31/2016	1	-32	N/A	-18	N/A
5/31/2016	1	-31	N/A	-17	N/A
2/29/2016	1	-20	N/A	-18	N/A
11/30/2015	1	-20	N/A	-17	N/A
8/31/2015	1	-21	N/A	-18	N/A
5/31/2015	1	-20	N/A	-18	N/A
2/28/2015	0	-17	N/A	-17	N/A
11/30/2014	0	-17	N/A	-18	N/A
8/31/2014	0	-16	N/A	-17	N/A
5/31/2014	0	-17	N/A	-17	N/A
2/28/2014	0	-17	N/A	-16	N/A
11/30/2013	0	-18	N/A	-15	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DMN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DMN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: DMN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DMNの収益 ( 103% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: DMNの収益 ( 103% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DMNの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Diamyd Medical 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Diamyd Medical AB (publ) Hits a Recruitment Milestone in DIAGNODE-3 Phase 3 Trial

Diamyd Medical AB (publ), Annual General Meeting, Dec 05, 2024

Full year 2024 earnings released: kr1.52 loss per share (vs kr1.48 loss in FY 2023)

Diamyd Medical AB (publ) to Report Q1, 2025 Results on Jan 29, 2025

Diamyd Medical to Pursue Accelerated Approval Pathway for Type 1 Diabetes Precision Medicine

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

New major risk - Share price stability

Third quarter 2024 earnings released

Diamyd Medical AB (publ) to Report Q4, 2024 Results on Nov 14, 2024

Diamyd Medical AB (publ) Updates on the Registrational Phase 3 Trial

Independent Chairman recently sold €56k worth of stock

Recruitment Milestone Reaches in Diamyd® Phase 3 Trial

Second quarter 2024 earnings released

New major risk - Share price stability

First quarter 2024 earnings released

In-Depth Analysis of Diamyd Medical AB (publ)'s Phase II Trial Further Supports Value of Presented Insulin Production

Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Diamyd Medical AB (publ) to Report Fiscal Year 2023 Results on Nov 30, 2023

Diamyd Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 69.834709 million.

Diamyd Medical AB (Publ) Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset

Diamyd Medical AB (publ) Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection

Diamyd Medical AB (publ) to Report Q2, 2024 Results on Mar 27, 2024

Full year 2023 earnings released: kr1.30 loss per share (vs kr1.35 loss in FY 2022)

Diamyd Medical AB (Publ) Announces Changes of the Board

Diamyd Medical AB (Publ) Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US

New minor risk - Shareholder dilution

Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Diamyd Medical Receives Patent Protection in the US and Japan for Gaba Formulation Remygen

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.52 loss in 1Q 2022)

Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Eurasia

Diamyd Medical AB (Publ) Announces US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

Full year 2022 earnings released: kr1.35 loss per share (vs kr0.86 profit in FY 2021)

All Patients in DIAGNODE-B Have Received an Additional (Booster) Injection of Diamyd

Diamyd Medical AB (publ) to Report Q3, 2023 Results on Jun 28, 2023

Third quarter 2022 earnings released

Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022

Diamyd Medical AB (publ) Announces First Patient Enrolled in its Phase III Trial DIAGNODE-3

Director recently sold €99k worth of stock

Diamyd Medical AB Announces New Clinical Trial Will Evaluate an Additional Injection (Booster) with Diamyd

Second quarter 2022 earnings released

Clinical Trial in Type 1 Diabetes with Diamyd Medical's Remygen Is Fully Recruited

Diamyd Medical Proceeds with Initiation of Type 1 Diabetes Phase III Trial in Europe

First quarter 2022 earnings: Revenues miss analyst expectations

Diamyd Medical AB Patent for Intralymphatic Injection of GAD in Autoimmune Diabetes to Be Granted in China

Diamyd Medical Announces Australia Grants as the First Region Diamyd Medical A Broadening of A Patent for Intralymphatic Injection of Antigens in Autoimmune Diabetes

Director recently sold €358k worth of stock

Investor sentiment deteriorated over the past week

Diamyd Medical Pauses Start of Phase III Trial

Full year 2021 earnings released: EPS kr0.86 (vs kr0.14 in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.84 (vs kr0.14 in FY 2020)

Investor sentiment deteriorated over the past week

Diamyd Medical AB Receives First Regulatory Approval to Start the Phase III Trial DIAGNODE-3 with the Diabetes Vaccine Diamyd®

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Diamyd Medical AB (Publ) Announces 24-Month Follow-Up of Phase IIb Diamyd® Clinical Trial Indicates Continued Similar Progression After 15 Months

the 24-Month Follow-Up of DIAGNODE-2 with the Diabetes Vaccine Diamyd® Will Be Presented in Early July

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released

Diamyd Medical AB (publ) Announces Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd®

Investor sentiment improved over the past week

New 90-day high: €3.62

Investor sentiment improved over the past week

New 90-day low: €2.46

Director recently sold €116k worth of stock

New 90-day low: €2.73

Diamyd Medical AB Announces Positive Safety Evaluation of Remygen® in High Dose and in Combination with Alprazolam Gives the Go-Ahead for the Continuation of the Trial

Meta-Analysis Updated with DIAGNODE-2 Results Provides Further Support for A Precision Medicine Approach Using Diamyd Medical

Diamyd Medical and Critical Path Institute Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes

Insider recently sold €34k worth of stock

Diamyd Medical AB (publ) Announces Operational Update About the Diabetes Vaccine Diamyd

Diamyd Medical AB (publ) to Report Fiscal Year 2021 Results on Oct 06, 2021